ArticleInternational journal of clinical and experimental pathology2019
Apigenin attenuates PM2.5-induced airway hyperresponsiveness and inflammation by down-regulating NF-κB in murine model of asthma.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Apigenin: A Bioflavonoid with a Promising Role in Disease Prevention and Treatment.Biomedicines · 2024Review
- Apigenin Alleviates Autistic-like Stereotyped Repetitive Behaviors and Mitigates Brain Oxidative Stress in Mice.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Network pharmacology and experimental evidence: MAPK signaling pathway is involved in the anti-asthma roles ofHeliyon · 2024Article
- Indoor metabolites and chemicals outperform microbiome in classifying childhood asthma and allergic rhinitis.Eco-Environment & Health · 2023Article
- The effect of apigenin, an aryl hydrocarbon receptor antagonist, in Phthalate-Exacerbated eosinophilic asthma model.Journal of cellular and molecular medicine · 2023Article
- Desert particulate matter from Afghanistan increases airway obstruction in human distal lungs exposed to type 2 cytokine IL-13.Frontiers in medicine · 2023Article
- Unveiling the Ability of Witch Hazel (International journal of molecular sciences · 2022Article
- Effects of Intrauterine Infusion of Micronised Purified Flavonoid Fraction (MPFF) in Metritis-Diagnosed Dairy Cows Naturally Infected byVeterinary sciences · 2022Article
- Article
- MicroRNAs: Potential mediators between particulate matter 2.5 and Th17/Treg immune disorder in primary membranous nephropathy.Frontiers in pharmacology · 2022Article
- C-KitIranian journal of basic medical sciences · 2022Article
- Apigenin Ameliorates Scopolamine-Induced Cognitive Dysfunction and Neuronal Damage in Mice.Molecules (Basel, Switzerland) · 2021Article
- Fine particulate matter induces airway inflammation by disturbing the balance between Th1/Th2 and regulation of GATA3 and Runx3 expression in BALB/c mice.Molecular medicine reports · 2021Article
- The role of neutrophils in asthma.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2021Review
- Sulforaphane Alleviates Particulate Matter-Induced Oxidative Stress in Human Retinal Pigment Epithelial Cells.Frontiers in medicine · 2021Article
- Lactic Acid Bacteria Ameliorate Diesel Exhaust Particulate Matter-Exacerbated Allergic Inflammation in a Murine Model of Asthma.Life (Basel, Switzerland) · 2020Article
- Recent insights into the biological functions of apigenin.EXCLI journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to investigate the anti-inflammatory potential of the natural flavonoid apigenin to mitigate the airway inflammation in asthmatic mice exposed to particulate matter (PM) 2.5, and examine the possible mechanisms involved. BALB/c mice were sensitized and challenged with ovalbumin (OVA), then administered apigenin at a dose of 20 mg/kg/day, followed by PM2.5 exposure at a dose of 100 μg/mouse before prior to each challenge. The results showed that PM2.5 exposure aggravated airway hyper-responsiveness (AHR) and led to a mixed T helper (Th)2 cell/interleukin (IL)-17 response in asthmatic mice. Apigenin treatment markedly decreased both AHR and the percentage of eosinophils, as well as neutrophil infiltration in the bronchoalveolar lavage fluid (BALF) and lung tissue of OVA-sensitized and PM2.5-exposed mice. There were significant reductions in the levels of total serum immunoglobulin IgE and T-helper cell type 2 (Th2)-related cytokines (IL-4, IL-13) and Th17-related cytokine IL-17 in BALF. In addition, treatment with apigenin down-regulated the expression of nuclear factor kappa-light -chain-enhancer of activated B cells (NF-κB) p65 submit in lung tissue of asthmatic mice. These data suggest that apigenin exhibited both anti-allergic and anti-neutrophil-related inflammatory activity in a murine asthma model exposed to PM2.5, possibly through modulating IL-17 and down-regulating the expression of NF-κB. Thus, apigenin may be a promising candidate for preventing PM2.5 exposure-enhanced pre-existing asthma.
Indexed as
Identifiers
31933758PMC6949738W3010666495What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.